Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Mouse IgG2a Monoclonal Antibody.
Clone: CL2.
Isotype: Mouse IgG2a Kappa.
Source:The anti-human CD62E (E-selectin) monoclonal antibody (clone: CL2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: CL2) specifically binds to human CD62E (E-selectin).
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD62E (E-selectin) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD62E (E-selectin) monoclonal antibody of clone CL2 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer’s disease
Kuhn, C., et al. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2309221120. doi: 10.1073/pnas.2309221120. PMID: 37669420
Nasal administration of the anti-CD3 monoclonal antibody (clone CL2) induced regulatory T cells (Tregs), ameliorating disease in mouse models of Alzheimer’s disease, multiple sclerosis, diabetes, lupus, and arthritis. In a progressive EAE model, it reduced microglia and astrocyte inflammation in the CNS, supporting its potential to address Treg dysfunction in Alzheimer’s disease.
Tags: anti-human CD62E (E-selectin) CL2; anti-human CD62E (E-selectin) (CL2) in vivo antibody
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Wang, L., et al. Blood Adv. 2024 Jan 23;8(2):470-481. doi: 10.1182/bloodadvances.2023005827. PMID: 38231088
Flow cytometric analysis using the anti-CD3ε antibody (clone CL2) assessed T cell activation in B-hCD3E and B-hCD3EDG mice treated with anti-CD3/CD19 and anti-CD3/BCMA bispecific antibodies. In MC38-based tumor models, blinatumomab and anti-CD3/BCMA antibodies dose-dependently inhibited tumor growth, highlighting the model’s utility for evaluating T-cell engager efficacy.
Tags: anti-human CD62E (E-selectin) CL2 antibody; anti-human CD62E (E-selectin) antibody (clone CL2)
Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies
Schmied, L., et al. Immun Inflamm Dis. 2021 Jun;9(2):265-282. doi: 10.1002/iid3.426. PMID: 33945643
Mice co-injected intravenously with 5 μg of anti-CD3 (clone CL2) and an anti-cytokine cocktail (anti-IL-2, IL-6, IFN-γ, TNF-α, 30 mg/kg each) showed transient improvement in cytokine release syndrome (CRS) features. The model, replicating T-cell activation and extramedullary hematopoiesis, supports evaluation of anti-cytokine strategies for human CRS.
Tags: anti-human CD62E (E-selectin) CL2 in animal model; anti-human CD62E (E-selectin) antibody (clone CL2)
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model
Prodeus, A., et al. Sci Rep. 2022 Mar 3;12(1):3456. doi: 10.1038/s41598-022-06953-7. PMID: 35241728
A humanized CD3E mouse model evaluated the anti-CD3ε antibody (clone CL2), which activated T cells in vitro and depleted nearly 100% of peripheral B cells in vivo when targeting CD20. The model, showing normal thymic development, supports preclinical testing of T-cell engagers like anti-CD3/CD19 and anti-CD3/BCMA antibodies.
Tags: anti-human CD62E (E-selectin) CL2 in cancer research; anti-human CD62E (E-selectin) antibody CL2
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Mok, S., et al. J Natl Cancer Inst. 2010 Dec 15;102(24):1843-54. doi: 10.1093/jnci/djq419. PMID: 21116835
Intraperitoneal administration of anti-mouse and anti-human CCL2 antibodies (2 mg/kg/dose, twice weekly) with temozolomide prolonged survival in C57BL/6 mice bearing GL261 glioma (8/10 survived >70 days vs. 3/10 with control IgG, P=0.0359). The treatment reduced tumor-associated macrophages and myeloid-derived suppressor cells, enhancing anti-tumor immune responses.
Tags: anti-human CD62E (E-selectin) CL2; clone CL2 of human CD62E (E-selectin) antibody
For more references about anti-human CD62E (E-selectin) antibody (CL2), please contact our scientific support team with message@sydlabs.com.
Copyright © 2009-2025 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.
Friend Link: Ushelf